5-Amino-1MQ Guide

What Is 5-Amino-1MQ?

5-Amino-1MQ is a synthetic small molecule—not a peptide, despite its prevalence in the research peptide market. It's a competitive inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation and deactivation of nicotinamide, a NAD+ precursor. By inhibiting NNMT, 5-Amino-1MQ preserves NAD+ availability in cells, leading to increased cellular energy production and metabolic rate.

NAD+ is a critical coenzyme in mitochondrial respiration (the process that generates ATP, cellular energy) and in sirtuin activation (proteins involved in longevity, metabolic health, and stress resistance). Higher NAD+ levels are associated with improved metabolic rate, reduced fat accumulation, and enhanced physical performance in preclinical models.

The compound was originally identified in a high-throughput screening campaign by researchers seeking novel approaches to metabolic dysfunction. It's become popular in the research community as an oral or subcutaneous tool for investigating NAD+ metabolism and fat oxidation.

How Does 5-Amino-1MQ Work?

5-Amino-1MQ operates through a specific metabolic pathway: it inhibits NNMT, which normally converts nicotinamide (niacin) into N-methylnicotinamide (a form that's excreted and unavailable for NAD+ synthesis). By blocking this enzyme, 5-Amino-1MQ redirects nicotinamide toward the NAD+ salvage pathway, increasing intracellular NAD+ levels.

Mechanism breakdown:

• Inhibits NNMT enzyme
• Increases NAD+ bioavailability
• Activates sirtuins (SIRT1–7), metabolic regulators
• Enhances mitochondrial respiration and ATP production
• Shifts metabolism toward lipid oxidation (fat burning)
• Reduces acetyl-CoA carboxylase (ACC) activity, suppressing fatty acid synthesis

The end result is increased energy expenditure and metabolic flexibility—the body's ability to switch between carbohydrate and fat oxidation based on availability. Preclinical studies in obese mouse models showed significant reductions in fat mass without changes in food intake, suggesting the compound promotes intrinsic metabolic improvements rather than appetite suppression alone.

Additionally, elevated NAD+ levels may enhance muscle mitochondrial function, improve endurance capacity, and support cellular stress resistance—effects observed in animal models and in vitro studies.

What Does the Research Show?

5-Amino-1MQ is a relatively newer research compound compared to older peptides like BPC-157 or ipamorelin. Most published data comes from preclinical (cell and animal) studies.

Key research findings:

• Obesity and fat loss: In ob/ob mice (genetically obese models), 5-Amino-1MQ reduced body weight, total fat mass, and liver triglycerides without reducing food intake, indicating direct metabolic improvement.
• NAD+ elevation: Confirmed increases in intracellular NAD+ levels in adipose tissue and muscle, validating the proposed mechanism.
• Metabolic rate: Animal studies showed increased oxygen consumption (VO₂) and energy expenditure in brown and white adipose tissue.
• Glucose homeostasis: Improved insulin sensitivity and reduced fasting glucose in high-fat diet models.
• Mitochondrial function: Enhanced ATP production and improved mitochondrial respiratory capacity in skeletal muscle.

Human data is extremely limited. A small Phase 1b study presented at scientific conferences showed good tolerability in a small cohort with dose-dependent NAD+ elevation, but formal peer-reviewed publication and larger trials are lacking. Most community reports are anecdotal.

The lack of extensive human safety and efficacy data makes 5-Amino-1MQ suitable only for research purposes at this stage.

5-Amino-1MQ vs. Other Fat Loss Compounds

5-Amino-1MQ operates through a distinct mechanism compared to traditional fat loss peptides. Here's how it compares:

Key differences:

• AOD-9604 and Fragment 176-191 are GH-derived peptides that directly trigger lipolysis (fat cell breakdown) through GH receptor activation. They've been studied in humans and show modest fat loss effects.
• GH secretagogues (ipamorelin, CJC-1295) work indirectly—they increase endogenous GH, which then promotes fat oxidation and lean mass gain as secondary effects.
• 5-Amino-1MQ is a metabolic enhancer that works at the mitochondrial/cellular energy level, improving the body's intrinsic ability to burn fat and generate energy without direct hormonal manipulation.

Dosage & Administration

Cycle recommendations: 4–12 weeks on, followed by a break. Longer cycles (8–12 weeks) are common in research protocols to allow metabolic adaptation. Some researchers use shorter 4-week cycles with brief breaks to minimize potential downregulation of NNMT inhibition.

Timing: Oral doses are typically taken with or without food (food may slightly delay absorption but doesn't significantly impair efficacy). Subcutaneous injections are administered once daily, usually in the morning or evening.

Half-life: Not formally established in humans. Preclinical data suggests a relatively short half-life (hours), though tissue accumulation and NAD+ elevation suggest longer-term effects than direct pharmacokinetics alone would predict.

Note: Subcutaneous injection requires proper reconstitution with bacteriostatic water and sterile injection technique. Always use sterile, pharmaceutical-grade materials.

Stacking and Protocol Combinations

5-Amino-1MQ can be combined with other compounds for complementary metabolic and fat-loss effects, though such stacking remains experimental.

5-Amino-1MQ + GH secretagogues (ipamorelin, CJC-1295): Synergistic for body composition. GH secretagogues promote lean mass gain; 5-Amino-1MQ enhances fat oxidation and energy expenditure. Theoretical benefit: faster fat loss with retained muscle. Risk: compounded nausea (both can cause GI distress), unpredictable metabolic effects, no formal safety data for combination. Used occasionally in advanced research protocols.

5-Amino-1MQ + AOD-9604 or Fragment 176-191: Direct + metabolic fat loss pathway. AOD/Fragment directly triggers lipolysis; 5-Amino-1MQ enhances mitochondrial fat oxidation. Theory: maximal fat loss efficiency. Practical concern: no studies on safety or true synergy. Some users report improved results; others see no additional benefit beyond either compound alone.

5-Amino-1MQ + NMN/NR (NAD+ boosters): Both increase NAD+, but via different pathways. NMN/NR provide direct precursor; 5-Amino-1MQ preserves existing nicotinamide. Combined use might achieve higher absolute NAD+ levels, but optimal dosing and timing are not established. Some researchers theorize potential redundancy rather than synergy.

5-Amino-1MQ + Exercise/Diet: Not a "stack" but critical for results. 5-Amino-1MQ enhances metabolic capacity but does not create fat loss in a caloric surplus. Combine with: caloric deficit (20% below maintenance), protein at 0.8–1.2g/lb, resistance training 3–4x weekly, and 150 min moderate cardio weekly for optimal results.

Results Timeline and Expectations

Unlike acute peptides like Melanotan II, 5-Amino-1MQ works through gradual metabolic optimization.

Week 1: NAD+ elevation occurs within hours to days. Energy levels may increase subtly. Most users don't notice dramatic changes yet. Appetite may shift slightly. Some report improved mood or focus.

Weeks 2–3: Noticeable increases in energy during workouts and daily activity. Endurance in cardio slightly improves. Some users report better sleep quality. Body weight may remain stable or decrease slightly (depending on diet). Metabolic rate increases measurably (evidenced by elevated resting heart rate, increased body heat).

Weeks 4–8: Most dramatic phase for fat loss if combined with diet and exercise. Average fat loss in research protocols: 0.5–1.5 lbs/week in overweight/obese populations. Lean mass is preserved or increased due to sirtuin activation (despite being in a deficit). Strength in lifting may increase despite caloric restriction (due to improved mitochondrial efficiency). Skin condition may improve (sirtuins activate cellular stress resistance).

Weeks 8–12: Results plateau as the body adapts. Continued fat loss is slower. Some users cycle off for 4–8 weeks, then restart for renewed effect (addresses potential NNMT upregulation). Others continue at same dose year-round with maintenance results.

Post-discontinuation: NAD+ levels decline back toward baseline over 1–2 weeks. Fat loss halts (though fat mass loss is permanent). Energy may feel lower temporarily. Many users feel better the first few weeks back — suggests some metabolic oversuppression or down-regulation tolerance. Restarting after a break typically produces results again (suggests adaptation reversibility).

NNMT Inhibition and NAD+ Biology

Understanding the biochemistry provides context for efficacy and dosing.

NNMT enzyme: Nicotinamide N-methyltransferase (NNMT) is a Phase I detoxification enzyme found in liver, kidney, and adipose tissue. Its normal function is to methylate nicotinamide (vitamin B3) into N-methylnicotinamide (NMN), which is then excreted. This process consumes SAM (S-adenosyl methionine), a critical methyl donor used across the body. NNMT overexpression (observed in obesity, metabolic syndrome, and aging) leads to nicotinamide depletion and reduced NAD+ bioavailability.

NAD+ salvage pathway: By inhibiting NNMT, 5-Amino-1MQ redirects nicotinamide away from methylation and toward salvage pathway recovery of NAD+. This increases intracellular NAD+ levels, reactivating sirtuins (SIRT1–7) and PARPs (poly-ADP-ribose polymerases), cellular stress sensors that regulate mitochondrial function, metabolism, and longevity pathways.

NNMT and obesity: NNMT expression increases in obese adipose tissue, leading to a "nicotinamide trap" — obesity begets NNMT overexpression, which depletes NAD+, which impairs mitochondrial function, which perpetuates obesity. Breaking this cycle by inhibiting NNMT represents a therapeutic leverage point.

Potential downregulation: With sustained NNMT inhibition, the body may upregulate NNMT expression as a compensatory mechanism, reducing efficacy over time. This is why cycling (4–12 weeks on, 4–8 weeks off) is recommended — it prevents adaptive downregulation of the inhibitor's target and maintains sensitivity.

Oral vs. Subcutaneous Administration

5-Amino-1MQ can be dosed orally or via subcutaneous injection, each with pros and cons.

Oral administration (50–150 mg daily):

• Pros: Non-invasive, no injection supplies needed, easy to scale dose, no injection site reactions.
• Cons: First-pass hepatic metabolism may reduce bioavailability, food interactions possible, GI side effects (nausea, loose stools), variable absorption between individuals.
• Best for: Beginners, those uncomfortable with injections, maintenance protocols.

Subcutaneous injection (150–500 mcg daily):

• Pros: Bypasses first-pass metabolism, higher bioavailability, lower doses needed, more predictable absorption, faster onset.
• Cons: Requires injection supplies and technique, potential for injection site irritation or infection, more complex reconstitution.
• Best for: Advanced users, those desiring maximal effect, clinical research protocols.

Bioavailability comparison: Oral bioavailability of 5-Amino-1MQ is estimated at 40–60% (though not formally published in humans). Subcutaneous avoids first-pass entirely, providing 100% bioavailability. This explains the dose difference: 100 mg oral ≈ 150 mcg subq (assuming 50% bioavailability). Some users experiment with both routes; many transition from oral to subq once familiar with protocols.

Side Effects & Safety Profile

5-Amino-1MQ exhibits a favorable tolerability profile in preclinical studies, with no major organ toxicity observed even at high doses in animal models. However, human safety data is extremely limited.

Reported side effects (from preclinical and anecdotal community reports):

• Headaches: Occasional reports, possibly related to metabolic shift or NAD+-dependent processes.
• Mild gastrointestinal upset: Transient nausea or loose stools reported by some users, typically resolving within days.
• Fatigue (rare): Unusual but reported in a small number of users; may indicate too-rapid metabolic adaptation.
• Injection site reactions: If using subcutaneous route, transient redness or mild irritation at injection sites (standard for all SQ peptides).

What we don't know:

• Long-term safety in humans (data beyond 12 weeks is absent)
• Effects in specific populations (pregnancy, liver disease, kidney disease)
• Drug interactions with common medications
• Optimal cycle length and off-period duration

Monitoring: If using 5-Amino-1MQ, periodic metabolic panels (glucose, lipids, liver and kidney function) and NAD+ level testing are recommended, though NAD+ testing is not standard in most clinical labs.

Research Pipeline and Future Development

5-Amino-1MQ is at an earlier stage of development compared to established peptides like BPC-157 or approved drugs like PT-141. Understanding the research timeline contextualizes its current status.

Preclinical discovery: 5-Amino-1MQ was identified as an NNMT inhibitor through high-throughput screening campaigns by researchers investigating novel metabolic targets. Initial publications in scientific literature (2015 onwards) demonstrated efficacy in cell culture and animal models of obesity, metabolic syndrome, and age-related metabolic dysfunction.

Key published research: Neelakantan et al. (University of Texas), Kannt et al. (University of Bonn), and Brachs et al. published foundational work on NNMT inhibition and metabolic effects. Studies consistently showed fat loss, improved glucose homeostasis, and elevated NAD+ in animal models. These papers generated significant interest in NAD+-based interventions for metabolic disease.

Clinical translation attempts: At least one Phase 1b human study was presented at scientific conferences (exact status unpublished). Results: Oral dosing of 50–200 mg was well-tolerated, produced dose-dependent NAD+ elevation, and showed early hints of improved metabolic markers. However, no Phase II or III trials have been initiated, likely due to: regulatory challenges (NNMT inhibition is a novel mechanism with no approved precedent), difficulty securing funding without patent protection, and competition from other NAD+ approaches (NMN, NR, resveratrol).

Competitive landscape: NMN and NR (NAD+ precursors) have progressed further clinically and are available as dietary supplements. They work via a different mechanism (providing NAD+ substrate) rather than preserving it. Some researchers view NNMT inhibition as potentially superior or complementary, but the lack of completed human trials hampers adoption. Universities continue publishing preclinical work, but no major pharmaceutical company has licensed NNMT inhibition as a therapeutic target.

Future outlook: If Phase II/III trials were to be funded and conducted, 5-Amino-1MQ could potentially be developed for: obesity (given strong weight loss data in animal models), metabolic syndrome, age-related metabolic decline, or as an adjunct to exercise/diet interventions. Current timeline: Unlikely to achieve FDA approval within the next 5–10 years without significant private or institutional funding commitment. Research peptide market availability will likely continue as long as suppliers exist.

Cost-Benefit and Practical Considerations

Before committing to a 5-Amino-1MQ protocol, weigh practical considerations and alternatives.

Cost analysis: 5-Amino-1MQ research-grade costs approximately $0.10–0.50 per day (depending on dose, route, and supplier). A 12-week cycle costs roughly $80–150 — substantially cheaper than many pharmaceutical weight-loss interventions or ongoing supplement regimens. For comparison: semaglutide (Ozempic) costs $900–1,500/month; 5-Amino-1MQ is orders of magnitude less expensive, though it also has minimal human efficacy data.

Time to result: 4–8 weeks to see meaningful fat loss, requiring consistent diet and exercise. Faster than purely diet/exercise alone (which might take 12+ weeks for equivalent results), but slower than some other interventions. This makes it suitable for medium-term (3–6 month) body recomposition projects.

Sustainable use: Cycling protocols (on/off) make it suitable for long-term use without permanent health risks (assuming safety data holds). Unlike some hormonal interventions, discontinuation doesn't produce rebound effects — you simply stop getting the metabolic enhancement.

Alternatives if unavailable or ineffective: AOD-9604 (direct lipolytic peptide), NMN/NR (alternative NAD+ boosters), GH secretagogues (ipamorelin, CJC-1295), or conventional approaches (caloric deficit + exercise + potentially approved pharmacotherapy like phentermine or GLP-1 agonists). 5-Amino-1MQ fills a specific niche: metabolic enhancement via NAD+ elevation — not the only approach, but a viable option for those interested in experimental protocols.

Key Takeaways

• 5-Amino-1MQ is a small-molecule NNMT inhibitor that enhances NAD+ bioavailability and metabolic rate.
• Preclinical data is promising for fat loss and metabolic improvements, but human evidence is minimal.
• Typical dosing is 50–150 mg oral daily or 150–500 mcg subcutaneous daily, cycled for 4–12 weeks.
• Side effect profile appears favorable, but long-term human safety data is lacking.
• Best suited for research and experimental protocols under qualified supervision, not for self-directed use.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions